Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Azra Raza, MD, Magda Melcert, MD, Naomi Galili, PhD, Scott E. Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Shelby Young, RN, Lisa Meng, MS, Marsha Jones, MD, Gail L. Brown, MD, Jeffery Lancet, MD, Alan List, MD

Blood (2007) 110 (11): 1454.

https://doi.org/10.1182/blood.V110.11.1454.1454

Published: 2007

Journal Articles

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

Mary R. Stofega, PhD, Mingshan Cheng, MD, Huiping Ma, MD, Lidia Sambucetti, PhD, James G. Keck, PhD, Gail L. Brown, MD, Danying Cai, PhD

Blood (2006) 108 (11): 1161.

https://doi.org/10.1182/blood.V108.11.1161.1161

Published: 2006

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD

Blood (2004) 104 (11): 1428.

https://doi.org/10.1182/blood.V104.11.1428.1428

Published: 2004

Journal Articles

.

Peter Dean Emanuel, MD, Zhuo Wang, PhD, Danying Cai, PhD, Mary R. Stofega, PhD, James G. Keck, PhD, Zeev Estrov, MD, Gail L. Brown, MD, Jose L. Ochoa-Bayona, MD, Natalie Callander, MD

Blood (2004) 104 (11): 2372.

https://doi.org/10.1182/blood.V104.11.2372.2372

Published: 2004

NARROW

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

.

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome.

Telintra™ (TLK199) Enhances Granulocyte Colony-Stimulating Factor Production.

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only